Prokidney (PROK) Non-Current Deffered Revenue (2021 - 2022)
Prokidney (PROK) reported Non-Current Deffered Revenue of $7.7 million for Q2 2022, little changed on a QoQ basis from $7.7 million in Q1 2022.
Prokidney (PROK) has 2 years of Non-Current Deffered Revenue data on file, last reported at $7.7 million in Q2 2022.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $7.7 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $7.7 million (changed N/A YoY) and the FY2021 annual result came in at $7.7 million, changed N/A from the prior year.
- Non-Current Deffered Revenue held at $7.7 million in Q2 2022 per PROK's latest filing, from $7.7 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $7.7 million in Q3 2021 and bottomed at $7.7 million in Q3 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 225.10 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Prokidney | 259.72 Mn | 1.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 7.70 Mn |
| Mar 31, 2022 | 7.70 Mn |
| Dec 31, 2021 | 7.70 Mn |
| Sep 30, 2021 | 7.70 Mn |